semaglutide being taken off the market Novo cuts GLP-1 prices 70%, but revenue could grow in 2026 Despite FDA ruling, compounded GLP-1s

Researchers from Truveta, a health data analytics company, analyzed electronic health records for more than 18,000 adults, all of whom had overweight or obesity, who were taking these medications in the real world between May 2022 and September 2023

Lancet Gastroenterol Hepatol 2024

Case #2 highlights the role of recognizing potential risk factors for NA-AION

If drugs are needed, she says, semaglutide is the first or second drug of choice after metformin, the chief medication for treating type 2 diabetes

The closest performing GLP-1 medicine in terms of average weight loss is Novo Nordisks CagriSema, an Amylin/GLP-1 dual agonist, which had an average weight loss of 22.7% after 68 weeks in Phase 3 trials

The translational challenge in the development of new and effective therapies for endometriosis: a review of confidence from published preclinical efficacy studies